newsfilter
← Latest News
Business Wire·

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study